The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma

References

• Osgood E E. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9: 1–10
   PubMedGoogle Scholar
• Bergsagel D E, Sprague C C, Austin C, Griffith K M. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962; 21: 87–99
   PubMedGoogle Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Kumar S K, Rajkumar S V, Dispenzieri A, Lacy M Q, Hayman S R, Buadi F K, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2007
   Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 1999; 12: 171–191
   PubMed Web of Science ®Google Scholar
• Kumar S, Lacy M Q, Dispenzieri A, Rajkumar S V, Fonseca R, Geyer S, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161–167
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229–234
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
   PubMed Web of Science ®Google Scholar
• Phekoo K J, Schey S A, Richards M A, Bevan D H, Bell S, Gillett D, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299–304
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Prince H M. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951–966
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607
   PubMed Web of Science ®Google Scholar
• Rodon P, Linassier C, Gauvain J B, Benboubker L, Goupille P, Maigre M, et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol 2001; 66: 11–17
   PubMed Web of Science ®Google Scholar
• Greipp P R, San Miguel J, Durie B G, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007; 21: 2020–2024
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Greipp P R, Litzow M R, Henderson K J, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, Harrington D, Oken M M, Kyle R A, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575
   PubMed Web of Science ®Google Scholar
• Fonseca R, Harrington D, Oken M M, Dewald G W, Bailey R J, Van Wier S A, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62: 715–720
   PubMed Web of Science ®Google Scholar
• Fonseca R, Oken M M, Harrington D, Bailey R J, Van Wier S A, Henderson K J, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001; 15: 981–986
   PubMed Web of Science ®Google Scholar
• Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571
   PubMed Web of Science ®Google Scholar
• Worel N, Greinix H, Ackermann J, Kaufmann H, Urbauer E, Hocker P, et al. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001; 80: 345–348
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Rajkumar S V, Gertz M A, Fonseca R, Lacy M Q, Bergsagel P L, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82: 323–341
   PubMed Web of Science ®Google Scholar
• Fermand J P, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136
   PubMed Web of Science ®Google Scholar
• Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356
   PubMed Web of Science ®Google Scholar
• Forgeson G V, Selby P, Lakhani S, Zulian G, Viner C, Maitland J, et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 1988; 58: 469–473
   PubMed Web of Science ®Google Scholar
• Hussein M A, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95: 2160–2168
   PubMed Web of Science ®Google Scholar
• Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882–885
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86–89
   PubMed Web of Science ®Google Scholar
• Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130–1136
   PubMed Web of Science ®Google Scholar
• Anderson H, Scarffe J H, Ranson M, Young R, Wieringa G S, Morgenstern G R, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995; 71: 326–330
   PubMed Web of Science ®Google Scholar
• Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153–160
   PubMed Web of Science ®Google Scholar
• Kars A, Celik I, Kansu E, Tekuzman G, Ozisik Y, Guler N, et al. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma. Eur J Haematol 1997; 59: 100–104
   PubMed Web of Science ®Google Scholar
• Tsiara S N, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas K L. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 2000; 65: 118–122
   PubMed Web of Science ®Google Scholar
• Segeren C M, Sonneveld P, van der Holt B, Baars J W, Biesma D H, Cornellissen J J, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127–130
   PubMed Web of Science ®Google Scholar
• Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473
   PubMed Web of Science ®Google Scholar
• Rifkin R M, Gregory S A, Mohrbacher A, Hussein M A. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 2006; 106: 848–858
   PubMed Web of Science ®Google Scholar
• Lokhorst H M, Sonneveld P, Cornelissen J J, Joosten P, van Marwijk Kooy M, Meinema J, et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 1999; 23: 317–322
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 2004; 33: 623–628
   PubMed Web of Science ®Google Scholar
• Kumar S, Lacy M Q, Dispenzieri A, Rajkumar S V, Fonseca R, Geyer S, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485–490
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
   PubMed Web of Science ®Google Scholar
• Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V, et al. Dexamethasone+Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment in Newly Diagnosed Multiple Myeloma (MM): A Randomized Trial. ASH Annual Meeting Abstracts 2006; 108: 57
   Google Scholar
• Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S R, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, Prince H M, Harousseau J L, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132
   PubMed Web of Science ®Google Scholar
• Lacy M Q, Gertz M A, Dispenzieri A, Hayman S R, Geyer S, Kabat B, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179–1184
   PubMed Web of Science ®Google Scholar
• Zonder J A, Crowley J, Hussein M A, Bolejack V, Moore D F, Whittenberger B F, et al. Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232. ASH Annual Meeting Abstracts 2007; 110: 77
   Google Scholar
• Rajkumar S V, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 2006; 108: 799
   Google Scholar
• Rajkumar S V, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts 2007; 110: 174
   Google Scholar
• Kumar S, Dispenzieri A, Lacy M Q, Hayman S R, Buadi F K, Gastineau D A, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–2042
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Palumbo A. Management of newly diagnosed myeloma. Hematol Oncol Clin North Am 2007; 21: 1141–1156
   PubMed Web of Science ®Google Scholar
• Richardson P G, Chanan-Khan A, Schlossman R L, Munshi N C, Wen P, Briemberg H, et al. Phase II Trial of Single Agent Bortezomib (VELCADE(R)) in Patients with Previously Untreated Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2004; 104: 336
   Google Scholar
• Jagannath S, Durie B G, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776–783
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Zhang L, Fonseca R, Vesole D H, Greipp P R. Single Agent Bortezomib Is Associated with a High Response Rate in Patients with High Risk Myeloma. A Phase II Study from the Eastern Cooperative Oncology Group (E2A02). ASH Annual Meeting Abstracts 2006; 108: 3527
   Google Scholar
• Anderson K, Richardson P, Chanan-Khan A, Schlossman R, Munshi N, Oaklander A, et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study. J Clin Oncol (Meeting Abstracts) 2006; 24: 7504
   Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa A M, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505
   PubMed Web of Science ®Google Scholar
• Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
   PubMed Web of Science ®Google Scholar
• Cavo M, Patriarca F, Tacchetti P, Galli M, Perrone G, Petrucci M T, et al. Bortezomib (Velcade(R))-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2007; 110: 173
   Google Scholar
• Harousseau J L, Mathiot C, Attal M, Marit G, Caillot D, Mohty M MM, et al. VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. ASH Annual Meeting Abstracts 2007; 110: 450
   Google Scholar
• Bjorkstrand B, Goldstone A H, Ljungman P, Brandt L, Brunet S, Carlson K, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994; 15: 265–272
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735
   PubMed Web of Science ®Google Scholar
• Lee C K, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828
   PubMed Web of Science ®Google Scholar
• Knudsen L M, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33
   PubMed Web of Science ®Google Scholar
• Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917–922
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci M T, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Sureda A, Ribera J M, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759
   PubMed Web of Science ®Google Scholar
• Fermand J P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan K R, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G J, van Rhee F, Angtuaco E, Walker R, Epstein J, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ladeb S, Torjman L, Othman T B, Lakhal A, Romdhane N B, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805–1810
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294
   PubMed Web of Science ®Google Scholar
• Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R M, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 2273–2281
   PubMed Web of Science ®Google Scholar
• Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110–1120
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991; 325: 1267–1273
   PubMed Web of Science ®Google Scholar
• Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373
   PubMed Web of Science ®Google Scholar
• Einsele H, Schafer H J, Hebart H, Bader P, Meisner C, Plasswilm L, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411–418
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532–4539
   PubMed Web of Science ®Google Scholar
• Gerull S, Goerner M, Benner A, Hegenbart U, Klein U, Schaefer H, et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005; 36: 963–969
   PubMed Web of Science ®Google Scholar
• Crawley C, Iacobelli S, Bjorkstrand B, Apperley J F, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588–3594
   PubMed Web of Science ®Google Scholar
• Kroger N, Schwerdtfeger R, Kiehl M, Sayer H G, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755–760
   PubMed Web of Science ®Google Scholar
• Maloney D G, Molina A J, Sahebi F, Stockerl-Goldstein K E, Sandmaier B M, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454
   PubMed Web of Science ®Google Scholar
• Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, et al. A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. ASH Annual Meeting Abstracts 2007; 110: 3026
   Google Scholar
• Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056–4061
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, Hulin C, Bourhis J H, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L, Lahuerta J J, Sureda A, de la Rubia J, Garcia-Larana J, et al. Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study. ASH Annual Meeting Abstracts 2007; 110: 729
   Google Scholar
• Ladetto M, Pagliano G, Avonto I, Santo L, Ferrero S, Cavallo F, et al. Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients. ASH Annual Meeting Abstracts 2007; 110: 530
   Google Scholar
• Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495–502
   PubMed Web of Science ®Google Scholar
• Schaar C G, Kluin-Nelemans H C, Te Marvelde C, le Cessie S, Breed W P, Fibbe W E, et al. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005; 16: 634–639
   PubMed Web of Science ®Google Scholar
• Berenson J R, Crowley J J, Grogan T M, Zangmeister J, Briggs A D, Mills G M, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168
   PubMed Web of Science ®Google Scholar
• Stewart A K, Chen C I, Howson-Jan K, White D, Roy J, Kovacs M J, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170–8176
   PubMed Web of Science ®Google Scholar
• Sahebi F, Spielberger R, Kogut N M, Fung H, Falk P M, Parker P, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 825–829
   PubMed Web of Science ®Google Scholar
• Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248–1253
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J Y, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209–1218
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avonto I, Patriarca F, Crippa C, Petrucci M T, Rossini F, et al. Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis. ASH Annual Meeting Abstracts 2007; 110: 448
   Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Facon T, Mary J, Harousseau J, Huguet F, Berthou C, Grosbois B, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol (Meeting Abstracts) 2006; 24: 1
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Falcone A, Corradini P, Di Raimondo F, Giuliani N, et al. Oral Revlimid(R) Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. ASH Annual Meeting Abstracts 2006; 108: 800
   Google Scholar
• Mateos M V, Hernandez J M, Hernandez M T, Gutierrez N C, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165–2172
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164–168
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Piersantelli M-N, Visani G, Alesiani F, Brunori M, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159–2164
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Marit G, Caillot D, Casassus P, Facon T, Mohty M, et al. VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. ASH Annual Meeting Abstracts 2006; 108: 56
   Google Scholar